Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1994 Mar;111(3):956–960. doi: 10.1111/j.1476-5381.1994.tb14832.x

Antidepressant-like effects of CCKB antagonists in mice: antagonism by naltrindole.

M Derrien 1, C Durieux 1, B P Roques 1
PMCID: PMC1910081  PMID: 8019773

Abstract

1. The effects of selective CCKB agonists, BC 264 and BC 197 were investigated in the conditioned suppression of motility test in mice, an animal model used to select antidepressant drugs. The results showed that both CCKB agonists at doses of 3 and 30 micrograms kg-1, accentuated the suppression of motility in shocked mice and did not modify the behaviour of non-shocked mice. The effects of BC 264 were suppressed by L-365,260. 2. L-365,260 alone, at doses of 0.2 and 2 mg kg-1 decreased motor inhibition in shocked mice and had no effect in non-shocked mice. 3. The effects of L-365,260 observed in shocked mice were suppressed by naltrindole, a selective antagonist for delta-opioid receptors, suggesting the occurrence of physiological adverse interactions between CCK and opioid systems. 4. Together, these results suggest that CCKB antagonists could block centrally located CCKB receptors to produce antidepressant-like effects which could indirectly involve delta-opioid receptor stimulation.

Full text

PDF
956

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Amalric M., Cline E. J., Martinez J. L., Jr, Bloom F. E., Koob G. F. Rewarding properties of beta-endorphin as measured by conditioned place preference. Psychopharmacology (Berl) 1987;91(1):14–19. doi: 10.1007/BF00690919. [DOI] [PubMed] [Google Scholar]
  2. Baamonde A., Daugé V., Ruiz-Gayo M., Fulga I. G., Turcaud S., Fournié-Zaluski M. C., Roques B. P. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation. Eur J Pharmacol. 1992 Jun 5;216(2):157–166. doi: 10.1016/0014-2999(92)90356-9. [DOI] [PubMed] [Google Scholar]
  3. Bock M. G., DiPardo R. M., Evans B. E., Rittle K. E., Whitter W. L., Veber D. E., Anderson P. S., Freidinger R. M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J Med Chem. 1989 Jan;32(1):13–16. doi: 10.1021/jm00121a004. [DOI] [PubMed] [Google Scholar]
  4. Bozarth M. A., Wise R. A. Anatomically distinct opiate receptor fields mediate reward and physical dependence. Science. 1984 May 4;224(4648):516–517. doi: 10.1126/science.6324347. [DOI] [PubMed] [Google Scholar]
  5. Bradwejn J., Koszycki D., Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 1991 Jul;48(7):603–610. doi: 10.1001/archpsyc.1991.01810310021005. [DOI] [PubMed] [Google Scholar]
  6. Calenco-Choukroun G., Daugé V., Gacel G., Roques B. P. Lesion of dopamine mesolimbic neurons blocks behavioral effects induced by the endogenous enkephalins but not by a mu-opioid receptor agonist. Eur J Pharmacol. 1991 Dec 17;209(3):267–271. doi: 10.1016/0014-2999(91)90181-o. [DOI] [PubMed] [Google Scholar]
  7. Charpentier B., Durieux C., Pelaprat D., Dor A., Reibaud M., Blanchard J. C., Roques B. P. Enzyme-resistant CCK analogs with high affinities for central receptors. Peptides. 1988 Jul-Aug;9(4):835–841. doi: 10.1016/0196-9781(88)90130-1. [DOI] [PubMed] [Google Scholar]
  8. Charpentier B., Pelaprat D., Durieux C., Dor A., Reibaud M., Blanchard J. C., Roques B. P. Cyclic cholecystokinin analogues with high selectivity for central receptors. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1968–1972. doi: 10.1073/pnas.85.6.1968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Crawley J. N. Cholecystokinin accelerates the rate of habituation to a novel environment. Pharmacol Biochem Behav. 1984 Jan;20(1):23–27. doi: 10.1016/0091-3057(84)90094-7. [DOI] [PubMed] [Google Scholar]
  10. Dauge V., Bohme G. A., Crawley J. N., Durieux C., Stutzmann J. M., Feger J., Blanchard J. C., Roques B. P. Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264. Synapse. 1990;6(1):73–80. doi: 10.1002/syn.890060109. [DOI] [PubMed] [Google Scholar]
  11. Daugé V., Dor A., Féger J., Roques B. P. The behavioral effects of CCK8 injected into the medial nucleus accumbens are dependent on the motivational state of the rat. Eur J Pharmacol. 1989 Apr 12;163(1):25–32. doi: 10.1016/0014-2999(89)90391-9. [DOI] [PubMed] [Google Scholar]
  12. Daugé V., Kalivas P. W., Duffy T., Roques B. P. Effect of inhibiting enkephalin catabolism in the VTA on motor activity and extracellular dopamine. Brain Res. 1992 Dec 25;599(2):209–214. doi: 10.1016/0006-8993(92)90393-n. [DOI] [PubMed] [Google Scholar]
  13. Den Boer J. A., Westenberg H. G. Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology (Berl) 1990;102(1):85–94. doi: 10.1007/BF02245749. [DOI] [PubMed] [Google Scholar]
  14. Dourish C. T., O'Neill M. F., Coughlan J., Kitchener S. J., Hawley D., Iversen S. D. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol. 1990 Jan 25;176(1):35–44. doi: 10.1016/0014-2999(90)90129-t. [DOI] [PubMed] [Google Scholar]
  15. Faris P. L., Komisaruk B. R., Watkins L. R., Mayer D. J. Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia. Science. 1983 Jan 21;219(4582):310–312. doi: 10.1126/science.6294831. [DOI] [PubMed] [Google Scholar]
  16. Flood J. F., Garland J. S., Morley J. E. Evidence that cholecystokinin-enhanced retention is mediated by changes in opioid activity in the amygdala. Brain Res. 1992 Jul 10;585(1-2):94–104. doi: 10.1016/0006-8993(92)91194-j. [DOI] [PubMed] [Google Scholar]
  17. Fournié-Zaluski M. C., Coric P., Turcaud S., Lucas E., Noble F., Maldonado R., Roques B. P. "Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes. J Med Chem. 1992 Jun 26;35(13):2473–2481. doi: 10.1021/jm00091a016. [DOI] [PubMed] [Google Scholar]
  18. Garver D. L., Beinfeld M. C., Yao J. K. Cholecystokinin, dopamine and schizophrenia. Psychopharmacol Bull. 1990;26(3):377–380. [PubMed] [Google Scholar]
  19. Harro J., Kiivet R. A., Lang A., Vasar E. Rats with anxious or non-anxious type of exploratory behaviour differ in their brain CCK-8 and benzodiazepine receptor characteristics. Behav Brain Res. 1990 Jun 18;39(1):63–71. doi: 10.1016/0166-4328(90)90121-t. [DOI] [PubMed] [Google Scholar]
  20. Harro J., Vasar E. Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat. Eur J Pharmacol. 1991 Feb 14;193(3):379–381. doi: 10.1016/0014-2999(91)90156-k. [DOI] [PubMed] [Google Scholar]
  21. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D. C., Hunter J. C., Pinnock R. D., Woodruff G. N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A. 1990 Sep;87(17):6728–6732. doi: 10.1073/pnas.87.17.6728. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Itoh S., Katsuura G., Maeda Y. Caerulein and cholecystokinin suppress beta-endorphin-induced analgesia in the rat. Eur J Pharmacol. 1982 Jun 4;80(4):421–425. doi: 10.1016/0014-2999(82)90089-9. [DOI] [PubMed] [Google Scholar]
  23. Kalivas P. W., Richardson-Carlson R. Endogenous enkephalin modulation of dopamine neurons in ventral tegmental area. Am J Physiol. 1986 Aug;251(2 Pt 2):R243–R249. doi: 10.1152/ajpregu.1986.251.2.R243. [DOI] [PubMed] [Google Scholar]
  24. Kameyama T., Nagasaka M. Effects of apomorphine and diazepam on a quickly learned conditioned suppression in rats. Pharmacol Biochem Behav. 1982 Jul;17(1):59–63. doi: 10.1016/0091-3057(82)90263-5. [DOI] [PubMed] [Google Scholar]
  25. Kameyama T., Nagasaka M., Yamada K. Effects of antidepressant drugs on a quickly-learned conditioned-suppression response in mice. Neuropharmacology. 1985 Apr;24(4):285–290. doi: 10.1016/0028-3908(85)90133-9. [DOI] [PubMed] [Google Scholar]
  26. Katoh A., Nabeshima T., Ukai R., Kameyama T. Endorphins do not affect behavioral stress responses in mice. Peptides. 1992 Jul-Aug;13(4):737–739. doi: 10.1016/0196-9781(92)90180-b. [DOI] [PubMed] [Google Scholar]
  27. Latimer L. G., Duffy P., Kalivas P. W. Mu opioid receptor involvement in enkephalin activation of dopamine neurons in the ventral tegmental area. J Pharmacol Exp Ther. 1987 Apr;241(1):328–337. [PubMed] [Google Scholar]
  28. Lavigne G. J., Millington W. R., Mueller G. P. The CCK-A and CCK-B receptor antagonists, devazepide and L-365,260, enhance morphine antinociception only in non-acclimated rats exposed to a novel environment. Neuropeptides. 1992 Feb;21(2):119–129. doi: 10.1016/0143-4179(92)90522-x. [DOI] [PubMed] [Google Scholar]
  29. Lydiard R. B., Ballenger J. C., Laraia M. T., Fossey M. D., Beinfeld M. C. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992 May;149(5):691–693. doi: 10.1176/ajp.149.5.691. [DOI] [PubMed] [Google Scholar]
  30. Maldonado R., Derrien M., Noble F., Roques B. P. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses. Neuroreport. 1993 Jul;4(7):947–950. doi: 10.1097/00001756-199307000-00028. [DOI] [PubMed] [Google Scholar]
  31. Noble F., Derrien M., Roques B. P. Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain. Br J Pharmacol. 1993 Aug;109(4):1064–1070. doi: 10.1111/j.1476-5381.1993.tb13730.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. O'Neill M. F., Dourish C. T., Iversen S. D. Hypolocomotion induced by peripheral or central injection of CCK in the mouse is blocked by the CCKA receptor antagonist devazepide but not by the CCKB receptor antagonist L-365,260. Eur J Pharmacol. 1991 Feb 7;193(2):203–208. doi: 10.1016/0014-2999(91)90037-q. [DOI] [PubMed] [Google Scholar]
  33. Philipp E., Wilckens T., Friess E., Platte P., Pirke K. M. Cholecystokinin, gastrin and stress hormone responses in marathon runners. Peptides. 1992 Jan-Feb;13(1):125–128. doi: 10.1016/0196-9781(92)90150-2. [DOI] [PubMed] [Google Scholar]
  34. Rosenberg R., Ottosson J. O., Bech P., Mellergård M., Rosenberg N. K. Validation criteria for panic disorder as a nosological entity. Acta Psychiatr Scand Suppl. 1991;365:7–17. doi: 10.1111/j.1600-0447.1991.tb03096.x. [DOI] [PubMed] [Google Scholar]
  35. Shippenberg T. S., Bals-Kubik R., Herz A. Motivational properties of opioids: evidence that an activation of delta-receptors mediates reinforcement processes. Brain Res. 1987 Dec 15;436(2):234–239. doi: 10.1016/0006-8993(87)91667-2. [DOI] [PubMed] [Google Scholar]
  36. Singh L., Lewis A. S., Field M. J., Hughes J., Woodruff G. N. Evidence for an involvement of the brain cholecystokinin B receptor in anxiety. Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1130–1133. doi: 10.1073/pnas.88.4.1130. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Torgersen S. Genetic factors in anxiety disorders. Arch Gen Psychiatry. 1983 Oct;40(10):1085–1089. doi: 10.1001/archpsyc.1983.01790090047007. [DOI] [PubMed] [Google Scholar]
  38. Wiertelak E. P., Maier S. F., Watkins L. R. Cholecystokinin antianalgesia: safety cues abolish morphine analgesia. Science. 1992 May 8;256(5058):830–833. doi: 10.1126/science.1589765. [DOI] [PubMed] [Google Scholar]
  39. Wiesenfeld-Hallin Z., Xu X. J., Hughes J., Horwell D. C., Hökfelt T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci U S A. 1990 Sep;87(18):7105–7109. doi: 10.1073/pnas.87.18.7105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Willner P. Animal models of depression: an overview. Pharmacol Ther. 1990;45(3):425–455. doi: 10.1016/0163-7258(90)90076-e. [DOI] [PubMed] [Google Scholar]
  41. Wolf P., Olpe H. R., Avrith D., Haas H. L. GABAergic inhibition of neurons in the ventral tegmental area. Experientia. 1978 Jan 15;34(1):73–74. doi: 10.1007/BF01921910. [DOI] [PubMed] [Google Scholar]
  42. Wood P. L. Opioid regulation of CNS dopaminergic pathways: a review of methodology, receptor types, regional variations and species differences. Peptides. 1983 Sep-Oct;4(5):595–601. doi: 10.1016/0196-9781(83)90003-7. [DOI] [PubMed] [Google Scholar]
  43. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry. 1989 Jun;46(6):511–517. doi: 10.1001/archpsyc.1989.01810060031006. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES